STRATA Skin Sciences to Participate in June Dermatology Conferences
2024年6月4日 - 9:00PM
STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ:
SSKN), a medical technology company dedicated to developing,
commercializing, and marketing innovative products for the
treatment of dermatologic conditions, announces its participation
in two dermatology conferences in the month of June.
On June 1, STRATA has participated in the
inaugural Schweiger Symposium at the Jacob Javits Center in New
York City. The Symposium brought together dermatology providers and
leaders from multiple states for a day of presentations and
professional development sessions and was headed by Dr. Eric
Schweiger and the Schweiger Dermatology Group leadership team.
STRATA presented, had a marketing booth highlighting its XTRAC® and
TheraClear®X devices, and was available for discussions about the
applications and advantages of each. As of the end of the first
quarter of 2024 STRATA had XTRAC® and/or TheraClear®X devices in
over 35 individual offices that are part of the 110 Schweiger
Dermatology Group existing offices. For more information about the
Schweiger Symposium, please visit this link.
On June 21, STRATA will participate in the
Global Vitiligo Foundation Physician Education Summit at the
Marriott Indianapolis North in Indianapolis. The Summit is a
medical educational meeting designed to equip dermatologists with
knowledge and tools needed for accurate vitiligo identification,
diagnosis, and treatment. Leading vitiligo specialists will share
latest findings and facilitate discussions. STRATA will be
participating in a demonstration at the Summit, as well as
highlighting the benefits of vitiligo treatment using its XTRAC®
device. For more information about the Global Vitiligo Foundation
Physician Education Summit, please visit this link.
“Participating in these two conferences
highlights the key growth drivers for STRATA’s unique recurring
revenue business,” said Dr. Dolev Rafaeli, STRATA president and
CEO, “With penetration of 30% or more into the private equity
backed dermatology office groups, we intend to keep promoting best
practices across these groups and expanding the use of the XTRAC®
device for treatment beyond psoriasis and into vitiligo and
eczema.”
About STRATA Skin Sciences
STRATA Skin Sciences is a medical technology
company dedicated to developing, commercializing, and marketing
innovative products for the in-office treatment of various
dermatologic conditions, such as psoriasis, vitiligo, and acne. Its
products include the XTRAC® excimer laser, VTRAC® lamp
systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership Program.
STRATA’s popular partnership approach includes a fee per treatment
cost structure (versus an equipment purchase), installation and use
of the device, on-site training for practice personnel, service and
maintenance of the equipment, dedicated account and customer
service associates, and co-op advertising support to help raise
awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform
Act of 1995. These statements include but are not limited to the
Company’s plans, objectives, expectations and intentions and may
contain words such as “will,” “may,” “seeks,” and “expects,” that
suggest future events or trends. These statements, the Company’s
ability to launch and sell products recently acquired or to be
developed in the future, the Company’s ability to develop social
media marketing campaigns, direct to consumer marketing campaigns,
and the Company’s ability to build a leading franchise in
dermatology and aesthetics, are based on the Company’s current
expectations and are inherently subject to significant
uncertainties and changes in circumstances. Actual results may
differ materially from the Company’s expectations due to financial,
economic, business, competitive, market, regulatory, adverse market
conditions labor supply shortages, or supply chain interruptions
resulting from fiscal, political factors, international conflicts,
responses, or conditions affecting the Company, the medical device
industry and our customers and patients in general, as well as more
specific risks and uncertainties set forth in the Company’s SEC
reports on Forms 10-Q and 10-K. Given such uncertainties, any or
all these forward-looking statements may prove to be incorrect or
unreliable. The statements in this press release are made as of the
date of this press release, even if subsequently made available by
the Company on its website or otherwise. The Company does not
undertake any obligation to update or revise these statements to
reflect events or circumstances occurring after the date of this
press release. The Company urges investors to carefully review its
SEC disclosures available
at www.sec.gov and www.strataskinsciences.com.
Investor Contact:CORE
IR516-222-2560IR@strataskin.com
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 5 2024 まで 6 2024
Strata Skin Sciences (NASDAQ:SSKN)
過去 株価チャート
から 6 2023 まで 6 2024